Amazon, GoodRx Prescription Subscriptions Gain Traction Amid Rising US Healthcare Costs

Amazon.com and GoodRx are seeing a surge in demand for their prescription drug subscription services, as American consumers seek predictable ways to manage rising healthcare costs and navigate shrinking insurance coverage. The trend highlights a growing market for alternative payment models in the U.S. pharmaceutical space.

The Push From Rising Healthcare Costs

The growth in these services comes as consumers face increasing financial pressure from the traditional health insurance system. According to benefits consultants cited by Reuters, costs for employer-sponsored health plans are projected to rise by up to 11% in 2027.

This follows a period where millions of Americans have reportedly dropped individual plans offered under the Affordable Care Act. Many consumers are now in high-deductible plans, which require them to pay thousands of dollars out-of-pocket before coverage activates. "If someone is on multiple drugs, this kind of subscription can make a lot of sense," Truist analyst Jailendra Singh told Reuters.

Subscription Model Performance

Both companies have reported significant growth in their subscription offerings, which charge a flat monthly fee for access to a list of generic medications.

• GoodRx (GDRX): The company reported its total subscription revenue increased 39% year-over-year to $28.5 million in the second quarter. The number of subscription plans increased by 14% in the same period.
• Amazon (AMZN): Since launching its RxPass program in 2023, the number of customers has "grown nearly threefold," according to John Love, vice president at Amazon Pharmacy.

GoodRx CEO Wendy Barnes described the company's $14.99 per month "Companion" plan as "a complement to insurance" for consumers squeezed by rising costs.

Ad

Market Impact and Strategy

For investors, the strategic value of these services differs by company. For GoodRx, whose stock is up 22% this year according to the report, subscriptions are a direct and growing revenue stream. For Amazon, the $5 per month RxPass is viewed by analysts as a tool to enhance its Prime membership and drive traffic to its broader pharmacy and healthcare services, including One Medical.

"I wouldn’t even think of RxPass as a revenue product," Rajiv Leventhal, a healthcare analyst at EMarketer, told Reuters, noting its value is in strengthening the Prime ecosystem. Amazon's stock has risen 7% this year. The program's revenue is expected to be modest compared to the company's projected $828 billion in 2026 revenue, per LSEG data.

Competitive Landscape

The subscription model competes with other discount drug platforms. Mark Cuban’s Cost Plus Drugs, for example, offers generics based on acquisition cost plus a flat 15% markup, a model it claims offers better long-term value.

The scope of the subscription plans also varies. Amazon’s plan offers around 50 generic drugs, while GoodRx provides access to over 250. Both are a fraction of the roughly 30,000 generic drugs approved in the U.S., positioning them for consumers with common, recurring medication needs.